Follow us
SCIENTIFIC PUBLICATIONS AND COMMUNICATIONS
Liste des services
-
PATAS, a first-in-class therapeutic peptide biologic, improves whole-body insulin resistance and associated comorbidities in vivo
Schreyer E, Obringer C, Messaddeq N, Kieffer B, Zimmet P, Fleming A, Geberhiwot T, Marion V
Diabetes
2022 ; 71 : 1–14.
-
Relative Adipose Tissue Failure in Alström Syndrome Drives Obesity-Induced Insulin Resistance
Geberhiwot T, Baig S, Obringer C, Girard D, Dawson C, Manolopoulos K, Messaddeq N, Bel Lassen P, Clement K, Tomlinson J W, Steeds R P, Dollfus H, Petrovsky N, Marion V
Diabetes
2021 ; 70 : 364–376.
-
147-LB: PATAS, an Adipocyte-Targeted Peptide Approach to Treat Type 2 Diabetes and Associated ComorbiditiesÉlément de liste 1
Marion V
Diabetes
2019 ; 68 : 147-LB.
-
BBS-induced ciliary defect enhances adipogenesis, causing paradoxical higher-insulin sensitivity, glucose usage, and decreased inflammatory response
Marion V, Mockel A, De Melo C, Obringer C, Claussmann A, Simon A, Messaddeq N, Durand M, Dupuis L, Loeffler J-P, King P, Mutter-Schmidt C, Petrovsky N, Stoetzel C, Dollfus H
Cell Metabolism
2012 ; 16 : 363–377.
-
Transient ciliogenesis involving Bardet-Biedl syndrome proteins is a fundamental characteristic of adipogenic differentiation
Marion V, Stoetzel C, Schlicht D, Messaddeq N, Koch M, Flori E, Danse J-M, Mandel J-L, Dollfus H
Proc Natl Acad Sci U S A
2009 ; 106 : 1820–1825.
AdipoPharma SAS
Headquarters
Nextmed, Bâtiment eXplora (Bureau A203)
2 rue Marie Hamm
67000 Strasbourg
France
AdipoPharma SRL
Bioparc Gosselies
Belgique
AdipoPharma LLC
US Office Pittsburgh
Pennsylvania, USA
© Copyright AdipoPharma 2024 - Privacy Policy - Legal Notice